Report Detail
Global Depression Drugs Market Growth (Status and Outlook) 2019-2024
- RnM2938674 |
- 13 February, 2019 |
- Global |
- 138 Pages |
- LPI(LP Information) |
- Other
Depression is a mental health issue. It’s a condition that starts most often in early adulthood. It’s also more common in women. However, anyone at any age may suffer from depression. Depression affects the brain, so drugs that work in the brain may offer hope. Common antidepressants may help ease your symptoms, but there are many other options as well. Each drug used to treat depression works by balancing certain chemicals in your brain called neurotransmitters. Depression Drugs is drugs used for Depression.
The classification of Depression Drugs includes SSRIs, SNRIs and others, and the proportion of SSRIs in 2016 is about 47%, and the proportion of SNRIs in 2016 is about 34%.Depression Drugs is widely used in hospitals, clinics and other places. The most proportion of Depression Drugs is hospitals, and the proportion in 2016 is 679%. The trend of hospitals is increasing.
Market competition is not intense. Intellipharmaceutics, Pfizer, Eli Lilly, Astrazeneca, Lundbeck, Allergan, GSK, Otsuka Pharmaceutical, Takeda, NHU Group, Shionogi, APOTEX, Kanghong Pharma, HUAHAI, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
According to this study, over the next five years the Depression Drugs market will register a 2.9% CAGR in terms of revenue, the global market size will reach US$ 17300 million by 2024, from US$ 15000 million in 2019. In particular, this report presents the global revenue market share of key companies in Depression Drugs business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Depression Drugs market by product type, application, key companies and key regions.
This study considers the Depression Drugs value generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
SSRIs
SNRIs
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospitals
Clinics
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Intellipharmaceutics
Pfizer
Eli Lilly
Astrazeneca
Lundbeck
Allergan
GSK
Otsuka Pharmaceutical
Takeda
NHU Group
Shionogi
APOTEX
Kanghong Pharma
HUAHAI
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Depression Drugs market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Depression Drugs market by identifying its various subsegments.
Focuses on the key global Depression Drugs players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Depression Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Depression Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table of Contents
2019-2024 Global Depression Drugs Market Report (Status and Outlook)
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Depression Drugs Market Size 2014-2024
- 2.1.2 Depression Drugs Market Size CAGR by Region
- 2.2 Depression Drugs Segment by Type
- 2.2.1 SSRIs
- 2.2.2 SNRIs
- 2.2.3 Others
- 2.3 Depression Drugs Market Size by Type
- 2.3.1 Global Depression Drugs Market Size Market Share by Type (2014-2019)
- 2.3.2 Global Depression Drugs Market Size Growth Rate by Type (2014-2019)
- 2.4 Depression Drugs Segment by Application
- 2.4.1 Hospitals
- 2.4.2 Clinics
- 2.4.3 Others
- 2.5 Depression Drugs Market Size by Application
- 2.5.1 Global Depression Drugs Market Size Market Share by Application (2014-2019)
- 2.5.2 Global Depression Drugs Market Size Growth Rate by Application (2014-2019)
3 Global Depression Drugs by Players
- 3.1 Global Depression Drugs Market Size Market Share by Players
- 3.1.1 Global Depression Drugs Market Size by Players (2017-2019)
- 3.1.2 Global Depression Drugs Market Size Market Share by Players (2017-2019)
- 3.2 Global Depression Drugs Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Depression Drugs by Regions
- 4.1 Depression Drugs Market Size by Regions
- 4.2 Americas Depression Drugs Market Size Growth
- 4.3 APAC Depression Drugs Market Size Growth
- 4.4 Europe Depression Drugs Market Size Growth
- 4.5 Middle East & Africa Depression Drugs Market Size Growth
5 Americas
- 5.1 Americas Depression Drugs Market Size by Countries
- 5.2 Americas Depression Drugs Market Size by Type
- 5.3 Americas Depression Drugs Market Size by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Depression Drugs Market Size by Countries
- 6.2 APAC Depression Drugs Market Size by Type
- 6.3 APAC Depression Drugs Market Size by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Depression Drugs by Countries
- 7.2 Europe Depression Drugs Market Size by Type
- 7.3 Europe Depression Drugs Market Size by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Depression Drugs by Countries
- 8.2 Middle East & Africa Depression Drugs Market Size by Type
- 8.3 Middle East & Africa Depression Drugs Market Size by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Global Depression Drugs Market Forecast
- 10.1 Global Depression Drugs Market Size Forecast (2019-2024)
- 10.2 Global Depression Drugs Forecast by Regions
- 10.2.1 Global Depression Drugs Forecast by Regions (2019-2024)
- 10.2.2 Americas Market Forecast
- 10.2.3 APAC Market Forecast
- 10.2.4 Europe Market Forecast
- 10.2.5 Middle East & Africa Market Forecast
- 10.3 Americas Forecast by Countries
- 10.3.1 United States Market Forecast
- 10.3.2 Canada Market Forecast
- 10.3.3 Mexico Market Forecast
- 10.3.4 Brazil Market Forecast
- 10.4 APAC Forecast by Countries
- 10.4.1 China Market Forecast
- 10.4.2 Japan Market Forecast
- 10.4.3 Korea Market Forecast
- 10.4.4 Southeast Asia Market Forecast
- 10.4.5 India Market Forecast
- 10.4.6 Australia Market Forecast
- 10.5 Europe Forecast by Countries
- 10.5.1 Germany Market Forecast
- 10.5.2 France Market Forecast
- 10.5.3 UK Market Forecast
- 10.5.4 Italy Market Forecast
- 10.5.5 Russia Market Forecast
- 10.5.6 Spain Market Forecast
- 10.6 Middle East & Africa Forecast by Countries
- 10.6.1 Egypt Market Forecast
- 10.6.2 South Africa Market Forecast
- 10.6.3 Israel Market Forecast
- 10.6.4 Turkey Market Forecast
- 10.6.5 GCC Countries Market Forecast
- 10.7 Global Depression Drugs Forecast by Type
- 10.8 Global Depression Drugs Forecast by Application
11 Key Players Analysis
- 11.1 Intellipharmaceutics
- 11.1.1 Company Details
- 11.1.2 Depression Drugs Product Offered
- 11.1.3 Intellipharmaceutics Depression Drugs Revenue, Gross Margin and Market Share (2017-2019)
- 11.1.4 Main Business Overview
- 11.1.5 Intellipharmaceutics News
- 11.2 Pfizer
- 11.2.1 Company Details
- 11.2.2 Depression Drugs Product Offered
- 11.2.3 Pfizer Depression Drugs Revenue, Gross Margin and Market Share (2017-2019)
- 11.2.4 Main Business Overview
- 11.2.5 Pfizer News
- 11.3 Eli Lilly
- 11.3.1 Company Details
- 11.3.2 Depression Drugs Product Offered
- 11.3.3 Eli Lilly Depression Drugs Revenue, Gross Margin and Market Share (2017-2019)
- 11.3.4 Main Business Overview
- 11.3.5 Eli Lilly News
- 11.4 Astrazeneca
- 11.4.1 Company Details
- 11.4.2 Depression Drugs Product Offered
- 11.4.3 Astrazeneca Depression Drugs Revenue, Gross Margin and Market Share (2017-2019)
- 11.4.4 Main Business Overview
- 11.4.5 Astrazeneca News
- 11.5 Lundbeck
- 11.5.1 Company Details
- 11.5.2 Depression Drugs Product Offered
- 11.5.3 Lundbeck Depression Drugs Revenue, Gross Margin and Market Share (2017-2019)
- 11.5.4 Main Business Overview
- 11.5.5 Lundbeck News
- 11.6 Allergan
- 11.6.1 Company Details
- 11.6.2 Depression Drugs Product Offered
- 11.6.3 Allergan Depression Drugs Revenue, Gross Margin and Market Share (2017-2019)
- 11.6.4 Main Business Overview
- 11.6.5 Allergan News
- 11.7 GSK
- 11.7.1 Company Details
- 11.7.2 Depression Drugs Product Offered
- 11.7.3 GSK Depression Drugs Revenue, Gross Margin and Market Share (2017-2019)
- 11.7.4 Main Business Overview
- 11.7.5 GSK News
- 11.8 Otsuka Pharmaceutical
- 11.8.1 Company Details
- 11.8.2 Depression Drugs Product Offered
- 11.8.3 Otsuka Pharmaceutical Depression Drugs Revenue, Gross Margin and Market Share (2017-2019)
- 11.8.4 Main Business Overview
- 11.8.5 Otsuka Pharmaceutical News
- 11.9 Takeda
- 11.9.1 Company Details
- 11.9.2 Depression Drugs Product Offered
- 11.9.3 Takeda Depression Drugs Revenue, Gross Margin and Market Share (2017-2019)
- 11.9.4 Main Business Overview
- 11.9.5 Takeda News
- 11.10 NHU Group
- 11.10.1 Company Details
- 11.10.2 Depression Drugs Product Offered
- 11.10.3 NHU Group Depression Drugs Revenue, Gross Margin and Market Share (2017-2019)
- 11.10.4 Main Business Overview
- 11.10.5 NHU Group News
- 11.11 Shionogi
- 11.12 APOTEX
- 11.13 Kanghong Pharma
- 11.14 HUAHAI
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Depression Drugs . Industry analysis & Market Report on Depression Drugs is a syndicated market report, published as Global Depression Drugs Market Growth (Status and Outlook) 2019-2024. It is complete Research Study and Industry Analysis of Depression Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
